C irculating autoantibodies to the insulin receptor were first described by Flier et al. 1<2 in a group of patients with severe insulin resistance, hyperinsulinemia, and acanthosis nigricans. These antibodies appear to bind directly to determinants on or closely associated with the insulin receptor molecule.
these antibodies provide a potential tool for delineating the functional relationship between receptors for insulin and the insulin-like growth factors. 7 Such studies would be predicated upon the ability of such antibodies to specifically block the insulin receptor, without affecting the interaction between the ligand and the somatomedin receptor.
We have recently described an adult male patient with insulin-resistant diabetes mellitus and autoantibodies to the insulin receptor. 8 We now report the simultaneous occurrence of a serum factor (or factors) that inhibits both insulin and SM-C/IGF-I binding to specific receptors on cultured IM-9 lymphocytes.
METHODS
Preparation of sera. Serum samples were obtained from a 53-yr-old male patient who presented in 1978 with insulinresistant diabetes mellitus, fasting insulin levels of 295 /i,U/ml, mild hypergammaglobulinemia, and documented anti-insulin receptor antibodies. 8 Two years after initial diagnosis, the patient's hyperglycemia spontaneously improved, as evidenced by a fall in his daily insulin requirement from 500 to 30 U/day. Fasting serum samples obtained in 1978 and 1981 were acidified to pH 4.0 and treated with Norit-A charcoal to remove any insulin present in the serum. Additionally, a 40% ammonium sulfate precipitate was prepared by adding drops of a saturated solution of ammonium sulfate to serum at 4°C as described by Flier et al. 9 After the precipitate was resuspended up to its original volume in 0.15 M phosphate-buffered saline (PBS), both the resuspended precipitate and the supernatant were dialyzed twice for 10 h against 200 vol of PBS at 4°C. Preparation of peptides. SM-C was purified from Cohn Fraction IV of human plasma by our previously published methods 10 and demonstrated to be free of immunoreactive insulin. Previous work from our laboratory has indicated that SM-C and IGF-I have equal affinities for a specific receptor on the IM-9 cell, adding to the growing body of data that these two peptides are functionally, and probably structurally, identical. 11 -12 Crystalline porcine insulin was obtained from Elanco Products Company (Indianapolis, Indi-
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ana). 125 l-SM-C was prepared as previously described 11 and purified by gel filtration over a Sephadex G-50 column (1.0 x 120 cm) at 4°C. The 125 I-SM-C was then eluted with 100 mM Hepes buffer (pH 7.4) with 1% bovine serum albumin, 120mMNaCI, 1.2 mM MgSO 4 , 5mM KCI, 15mMNa acetate, 10 mM dextrose, and 1 mM EDTA.
125 l-insulin, with a specific activity of 100-120 AiCi//u,g, was prepared by modification of the method of Hunter and Greenwood.
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Binding studies. IM-9 cells, an established line of human lymphocytes, were grown in continuous culture in RPM1-1640 medium with 25 mM Hepes buffer (Grand Island Biological Co., Grand Island, New York), supplemented with 10% fetal bovine serum (Gibco), 4 mM L-glutamine (Gibco), penicillin (100 U/ml), and streptomycin (100 jug/ml). For binding assays, IM-9 cells in late log or early stationary phase were sedimented by centrifugation and resuspended in Hepes buffer at a concentration of 40 x 10 6 cells/ml. Aliquots of the cell suspension (0.5 ml) were incubated with equal volumes of buffer or serial dilutions of test or control serum for 2 h at 37°C. The cells were subsequently sedimented, washed three times in 5 ml of Hepes buffer at 22°C, and then resuspended in buffer for use in binding assays, as previously described. 11 Final cell concentrations in the binding assays were 10 7 cells/ml. The data from competitive binding assays were subjected to Scatchard analysis.
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RESULTS
Serum from our patient inhibited binding of insulin and SM-C to IM-9 cells equally. As depicted in Figure 1 The circulating inhibitor of both insulin and SM-C binding appeared to be an immunoglobulin. Pretreatment of test serum with staph-A (Pansorbin, Calbiochem) for 1 h at 4°C resulted in a 52% depletion of insulin-binding inhibitory capacity and a 59% depletion of SM-C-binding inhibitory capacity. Similarly, the serum inhibitor of insulin and SM-C binding was precipitated simultaneously and equally by 40% (NH 4 ) 2 SO 4 ( Figure 3) . Furthermore, the reconstituted (NH 4 ) 2 SO 4 fraction possessed identical inhibitory capacity for both insulin and SM-C binding.
DISCUSSION
Recognition of the role of antireceptor antibodies in the pathogenesis of type B insulin-resistant diabetes has contributed significantly to our understanding of the structure and function of membrane receptors for peptide hormones. 3 " 5 Initial reports of such naturally occurring antibodies suggested that they were highly specific for the insu- lin receptor. 1 -9 Thus, King et al. 7 employed anti-insulin receptor antibodies in an attempt to specifically block the insulin receptor and thereby demonstrate separate receptors for the mitogenic and metabolic activities of insulin and multiplication-stimulating activity. However, while the major effect of the antireceptor antibody was a dose-dependent inhibition of 125 l-insulin binding, the specificity of this blockade varied from tissue to tissue, and at higher antibody concentrations, a significant inhibition of 125 I-MSA binding to human fibroblasts was also observed.
In our case, the patient's serum inhibited insulin and SM-C binding to IM-9 cells to an identical degree, and appeared to decrease receptor affinity for both peptides, with little, if any, change in receptor number. Clinical improvement in the patient's diabetic state was accompanied by a synchronous decrease in antibody titer against both receptors. Whether the actual inhibitory factor is identical for each receptor remains uncertain, but the inhibitory capacity of serum was depleted identically by both staph-A and ammonium sulfate precipitation. These observations are consistent with any of the following hypotheses: (1) the insulin and SM-C receptors are identical (this is unlikely, since SM-C is 100 times more potent than insulin at displacing 125 I-SM-C from IM-9 cells, and vice versa); 11 (2) the antireceptor antibodies are polyclonal, and the presence of inhibitors of two receptors is coincidental (this too is unlikely, since the titers were identical and changed synchronously); (3) the insulin and SM-C receptors are physically linked on the IM-9 membrane, and binding of antibody to the insulin receptor inactivates or blocks the SM-C/IGF-I receptor; and (4) the insulin and SM-C receptors share a common subunit or, at least, a common antigenic site.
The possibility of structural homology between the insulin and SM-C/IGF-I receptors in supported by the functional interrelationship between these receptors. Both insulin and the SM peptides compete for occupancy of both receptors, and in general, the metabolic and mitogenic activities of each hormone are proportional to that peptide's affinity for the insulin or SM receptor, respectively. 6 - 15 We have also recently demonstrated that insulin and the somatomedin peptides IGF-I and -II not only bind to both receptors, but are capable of downregulating each receptor in proportion to their ability to occupy that receptor. 16 The structural similarity of the two IM-9 receptors is further exemplified by their identical susceptibility to tryptic digestion and alteration of pH. 16 It would thus appear that the homology between SM and insulin is not limited to peptide structure, but extends to their specific receptors. The interrelationship between those receptors, however, may vary from tissue to tissue. Insulin competes effectively for occupancy of the 125 I-SM-C/IGF-I receptor on IM-9 cells 11 -16 and chick embryo fibroblasts, but has a substantially decreased affinity for SM receptors on rat liver membranes. 17 Similarly, King et al. 7 have demonstrated a differential ability of anti-insulin receptor antibodies to inhibit 125 I-MSA binding to rat adipocytes, chick embryo fibroblasts, and human fibroblasts. These observations suggest the existence of heterogeneous population of SM receptors, with varying affinity not only for insulin and the SM peptides, 18>19 but for antireceptor antibodies as well. Kasuga et al., 19 employing affinity crosslinking and sodiumdodecyl-sulfate-polyacrylamide gel electrophoresis, have recently demonstrated two subtypes of SM/IGF receptors. One has a molecular weight of 220,000 in the nonreduced state and is nonreactive with insulin. The other has a molecular weight >300,000, is comprised of 130,000-mol.wt. subunits, and has a definite affinity for insulin. Note that this second receptor, in both its nonreduced and reduced form, is strikingly similar to the insulin receptor previously identified on IM-9 cells as well as on other tissues. 20>21 It is thus conceivable that the IM-9 insulin and SM-C/IGF-I receptors share significant structural as well as functional homology, and that our patient's serum contains antibodies directed against antigenically related subunits. Zapf et al. 6 have suggested that the striking structural homology between human proinsulin and the SM peptides indicates a common phylogenetic ancestor, and it is reasonable to hypothesize that the insulin and SM/IGF receptors similarly derive from a common ancestor membrane protein.
